Let’s look at the key reasons that are pushing Arcutis Biotherapeutics Inc (ARQT) to new highs

Arcutis Biotherapeutics Inc (NASDAQ: ARQT) kicked off on Tuesday, down -1.64% from the previous trading day, before settling in for the closing price of $11.59. Over the past 52 weeks, ARQT has traded in a range of $6.05-$16.20.

Healthcare Sector giant saw their annual sales surged by 379.27% over the last five years. While this was happening, its average annual earnings per share was recorded 65.01%. With a float of $103.03 million, this company’s outstanding shares have now reached $117.00 million.

The firm has a total of 296 workers. Let’s measure their productivity. In terms of profitability, gross margin is 89.43%, operating margin of -131.16%, and the pretax margin is -140.72%.

Arcutis Biotherapeutics Inc (ARQT) Breakdown of a Key Holders of the stock

Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Arcutis Biotherapeutics Inc is 11.97%, while institutional ownership is 103.19%. The most recent insider transaction that took place on Feb 03 ’25, was worth 105,893. In this transaction an insider of this company sold 8,338 shares at a rate of $12.70, taking the stock ownership to the 178,692 shares. Before that another transaction happened on Feb 03 ’25, when Company’s insider sold 19,301 for $12.70, making the entire transaction worth $245,123. This insider now owns 804,129 shares in total.

Arcutis Biotherapeutics Inc (ARQT) Recent Fiscal highlights

Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.28 per share during the current fiscal year.

According to the Wall Street analysts, stocks earnings will be around 65.01% per share during the next fiscal year.

Arcutis Biotherapeutics Inc (NASDAQ: ARQT) Trading Performance Indicators

Take a look at Arcutis Biotherapeutics Inc’s (ARQT) current performance indicators. Last quarter, stock had a quick ratio of 2.38. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 9.62.

For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.79, a number that is poised to hit -0.26 in the next quarter and is forecasted to reach -0.83 in one year’s time.

Technical Analysis of Arcutis Biotherapeutics Inc (ARQT)

Analysing the last 5-days average volume posted by the [Arcutis Biotherapeutics Inc, ARQT], we can find that recorded value of 1.88 million was lower than the volume posted last year of 1.92 million. As of the previous 9 days, the stock’s Stochastic %D was 10.07%. Additionally, its Average True Range was 0.90.

During the past 100 days, Arcutis Biotherapeutics Inc’s (ARQT) raw stochastic average was set at 41.25%, which indicates a significant increase from 6.82% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 45.24% in the past 14 days, which was lower than the 65.04% volatility it showed in the past 100 days.

At the time of writing, stock’s 50-day Moving Average is $13.47, while its 200-day Moving Average is $10.41. Now, the first resistance to watch is $11.55. This is followed by the second major resistance level at $11.69. The third major resistance level sits at $11.90. If the price goes on to break the first support level at $11.19, it is likely to go to the next support level at $10.98. Now, if the price goes above the second support level, the third support stands at $10.84.

Arcutis Biotherapeutics Inc (NASDAQ: ARQT) Key Stats

The company with the Market Capitalisation of 1.33 billion has total of 117,045K Shares Outstanding. Its annual sales at the moment are 59,610 K in contrast with the sum of -262,140 K annual income. Company’s last quarter sales were recorded 44,760 K and last quarter income was -41,540 K.